blog.aids.gov — HIV Policy & Programs. Research. New Media.
HIV Policy & Programs. Research. New Media.
Director of the Division of AIDS, NIAID
Over the next several weeks, the National Institute of Allergy and Infectious Diseases (NIAID) will post a series of entries here on AIDS.gov related to planning for the future of NIAID’s HIV/AIDS clinical trial networks. The awards supporting the six current HIV/AIDS networks are set to expire in 2013 and 2014. Building on the success…
Contrary to what you may have heard or read on the Internet, there is currently no cure for HIV/AIDS. While some say that there may never be a cure, I believe there is reason for hope. That’s because some of our best scientists are working on two distinct approaches to finding a cure for HIV/AIDS,…
If we routinely test everyone for HIV and treat those who are infected, could we bring an end to the HIV/AIDS epidemic? The test and treat concept, modeled on data from South Africa by scientists at the World Health Organization, is a provocative HIV prevention strategy. According to mathematical modeling, a successfully implemented test and…
This week, NIAID Director Anthony S. Fauci, M.D. and District of Columbia Mayor Adrian Fenty announced the launch of the D.C. Partnership for HIV/AIDS Progress, an ambitious, research-focused initiative designed to address the District’s HIV/AIDS epidemic. It’s a much-needed partnership. Our nation’s capital has one of the highest rates of HIV/AIDS in the country with…
Earlier this week, we commemorated World AIDS Day, a time to examine the progress that the global community has made against the HIV/AIDS global pandemic. While the statistics remain grim—more than 25 million deaths and 33 million people infected worldwide —there are glimmers of hope. Through the work of dedicated scientists, clinicians, and volunteers, the…
In late September, the U.S. federal government announced news on HIV vaccine research that sparked interest around the world. A trial called RV144, or the Thai HIV vaccine clinical trial , showed that the experimental vaccine regimen was safe and about 31 percent effective in preventing HIV infection. Although the vaccine regimen had a very…
Earlier this year, President Barack Obama signed the American Recovery and Reinvestment Act (ARRA) of 2009 into law to help stimulate the struggling U.S. economy. At the National Institute of Allergy and Infectious Disease (NIAID), part of the NIH, we have used ARRA funds to award high-quality, peer-reviewed grants focusing on research designed to help…
I just returned from the National HIV Prevention Conference in Atlanta where a sense of excitement and renewed enthusiasm for fighting the HIV/AIDS pandemic were buoyed by the new opportunities that the Obama administration brings. Conversely, there was also an underlying current of anxiety about how our country’s economic situation is affecting HIV prevention services….
